First decisions in with #ESP and #JPN qualified for the next round and #IRL, #CRC and #ZAM out.

#FIFAWWC #WM2023

lol, meine tipps für die nächsten spiele
#SUI vs #NOR 2:1
#JAP vs #CRC 2:1
#ESP vs #ZAM 2:1
#CAN vs #IRL 1:1
#FIFAWWC #fussball

3 #ESP #CRC 0

#WomansCup #WomansCup2023 #FrauenWM #ESPCRC #FrauenFußballWM2023

Das GING jetzt schnell

2 #ESP #CRC

#WomansCup #WomansCup2023 #FrauenWM #ESPCRC #FrauenFußballWM2023

Wer schaut auch?
#ESP vs #CRC

#ESPCRC #WomansCup #WomansCup2023 #FrauenWM #FrauenFußballWM2023

Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial #oncolytic #immunotherapy #intratumoral #CRC #cancer

https://jitc.bmj.com/content/11/5/e006774

'The Convention on the Rights of the Child’s Imprint on Judgments from the European Court of Human Rights: A Negligible Footprint?' by Trond Helland & Ragnhild Hollekim: https://doi.org/10.1080/18918131.2023.2204634

#echr #ecthr #CRC #legalmobilisation #lawfare #heuristic #childrensrights

*From #TumorBoardTuesday archives*

📖A lot can change in a year in ctDNA. Take a look at this January 2022 #ColorectalCancer case presentation by @aparna1024 & wrap up

Is there something you'd do different?
@MPishvaian @JohnEbbenMDPhD @pashtoonkasi

---
RT @TumorBoardTues
1/11
#TumorBoardTuesday case🎀⏲️

👉Deploying ctDNA to guide IO in #crc
🔥 topic led by @aparna1024

Read on for primer on mgmt of rectal ca w 🧬tools!

First…
https://twitter.com/TumorBoardTues/status/1481799635601707015

RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 3/6 #TumorBoardTuesday
🎥 TBT in a vid- Part 1:

@shafiarahman_ 's approach: pt eligible for EGFR-directed tx in #metastatic #CRC
🔹RAS/RAF WT- more important than side
🔹Bev or pan 1L? Trend toward pan, but is 🗝️actually that pt gets anti-EGFR in tx, 🚫necessarily 1L?

RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 3/6 #TumorBoardTuesday
🎥 TBT in a vid- Part 1:

@shafiarahman_ 's approach: pt eligible for EGFR-directed tx in #metastatic #CRC
🔹RAS/RAF WT- more important than side
🔹Bev or pan 1L? Trend toward pan, but is 🗝️actually that pt gets anti-EGFR in tx, 🚫necessarily 1L?

RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 3/6 #TumorBoardTuesday
🎥 TBT in a vid- Part 1:

@shafiarahman_ 's approach: pt eligible for EGFR-directed tx in #metastatic #CRC
🔹RAS/RAF WT- more important than side
🔹Bev or pan 1L? Trend toward pan, but is 🗝️actually that pt gets anti-EGFR in tx, 🚫necessarily 1L?

RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 3/6 #TumorBoardTuesday
🎥 TBT in a vid- Part 1:

@shafiarahman_ 's approach: pt eligible for EGFR-directed tx in #metastatic #CRC
🔹RAS/RAF WT- more important than side
🔹Bev or pan 1L? Trend toward pan, but is 🗝️actually that pt gets anti-EGFR in tx, 🚫necessarily 1L?

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ @ASCO 4/22 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 2👨🏻‍🏫

📌RAS Mutation = resistance to anti-EGFR therapy

📌KRAS muts:🕵🏻 detected by NGS- tissue or liquid bx #ctDNA

≈49% of #CRC= KRAS/NRAS muts
KRAS codons 12 (30%) & 13 (~8%) of exon 2. NRAS (exons 2, 3, 4)
📚https://pubmed.ncbi.nlm.nih.gov/26189770/

RT @JohnEbbenMDPhD
Here's the #TumorBoardTuesday thread- join in as @RischZack & @shafiarahman_ discuss the latest data around anti-EGFR tx strategies in #CRC! https://twitter.com/RischZack/status/1638330517530574851

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ @ASCO 4/22 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 2👨🏻‍🏫

📌RAS Mutation = resistance to anti-EGFR therapy

📌KRAS muts:🕵🏻 detected by NGS- tissue or liquid bx #ctDNA

≈49% of #CRC= KRAS/NRAS muts
KRAS codons 12 (30%) & 13 (~8%) of exon 2. NRAS (exons 2, 3, 4)
📚https://pubmed.ncbi.nlm.nih.gov/26189770/

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ @ASCO 4/22 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 2👨🏻‍🏫

📌RAS Mutation = resistance to anti-EGFR therapy

📌KRAS muts:🕵🏻 detected by NGS- tissue or liquid bx #ctDNA

≈49% of #CRC= KRAS/NRAS muts
KRAS codons 12 (30%) & 13 (~8%) of exon 2. NRAS (exons 2, 3, 4)
📚https://pubmed.ncbi.nlm.nih.gov/26189770/

RT @JohnEbbenMDPhD
Here's the #TumorBoardTuesday thread- join in as @RischZack & @shafiarahman_ discuss the latest data around anti-EGFR tx strategies in #CRC! https://twitter.com/RischZack/status/1638330517530574851

RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ @ASCO 4/22 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 2👨🏻‍🏫

📌RAS Mutation = resistance to anti-EGFR therapy

📌KRAS muts:🕵🏻 detected by NGS- tissue or liquid bx #ctDNA

≈49% of #CRC= KRAS/NRAS muts
KRAS codons 12 (30%) & 13 (~8%) of exon 2. NRAS (exons 2, 3, 4)
📚https://pubmed.ncbi.nlm.nih.gov/26189770/

RT @JohnEbbenMDPhD
Here's the #TumorBoardTuesday thread- join in as @RischZack & @shafiarahman_ discuss the latest data around anti-EGFR tx strategies in #CRC! https://twitter.com/RischZack/status/1638330517530574851

Here's the #TumorBoardTuesday thread- join in as @RischZack & @shafiarahman_ discuss the latest data around anti-EGFR tx strategies in #CRC!
---
RT @RischZack
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance 1/22 #TumorBoardTuesday #ColonCancerAwarenessMonth #OncTwitter @shafiarahman_

62 yo 👨🏼‍🦳 asymptomatic
🔦 Screening colonoscopy - sigmoid mass
🔬Biopsy + for pMMR/MSS adenocarcinoma
🩻Staging CT + for unresectable liver mets

🤨…
https://twitter.com/RischZack/status/1638330517530574851